Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Celdara Medical, LLC secured a $310,564 NIH SBIR/STTR award: Engineered Tregs as a therapy to Gaucher syndrome
Sep 01, 2026•4 days ago
United States
Description
SUMMARY
Lysosomal storage diseases (LSDs) are a group of inherited disorders that arise from mutations in genes
responsible for encoding lysosomal enzymes or transporters, which are critical for breaking down and exporting
complex macromolecules. When these enzymes or transporters fail to function properly, harmful substances
accumulate within cells, leading to widespread cellular dysfunction and severe clinical abnormalities. In
particular, the sphingolipidoses—a subset of LSDs—cause dysfunctio
Company Information
Company
Celdara Medical
Location
United States
About
Celdara Medical is a biotechnology company founded in 2008 and based in Lebanon, New Hampshire. The company focuses on transforming academic innovations into medicines that address challenging diseases. As a biopharmaceutical development partner, Celdara Medical connects university-based scientific discoveries with clinical applications, aiming to provide hope and health to patients.
The company offers programmatic pipeline development services to academic institutions and early-stage innovators. This includes scouting for valuable discoveries, providing developmental and financial support, and managing a diverse portfolio of therapies and diagnostics. Celdara Medical collaborates with premier research institutions in the US and Europe, working to advance early-stage innovations toward clinical development. Their efforts ultimately benefit patients suffering from difficult-to-treat conditions.
Predictive Intelligence
Strategic
ML-powered predictions for Celdara Medical's next move
United States